Interestingly, genetic and enzymatic silencing of HDAC6 recapitulated these effects, suggesting that the selective suppression of HDAC6 may represent an alternative therapeutic approach in Notch3-dependent malignancies, such as T-ALL and glioma [167,205]. This evidence concerns the gene HDAC6 and central nervous system cancer.